title: Successful treatment of eosinophilic otitis media using ramatroban: report of two cases.
abstract: OBJECTIVE
  The pathogenesis of eosinophilic otitis media is not yet fully understood. The purpose of this paper is to describe the clinical course of our two patients with eosinophilic otitis media and to discuss the pathogenesis and treatment of this intractable condition.
  
  
  METHODS
  Two cases of eosinophilic otitis media were treated with ramatroban.
  
  
  RESULTS
  The middle ear effusion has been well controlled in both patients for more than 1 year with minimal corticosteroid therapy.
  
  
  CONCLUSIONS
  Our experience suggests that the pathogenesis of eosinophilic otitis media is related to the pharmaceutical effects of ramatroban, i.e., inhibition of the thromboxane A2 receptor (TP) and the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2).
authors.affiliation: Department of Otolaryngology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennnodai, Tsukuba, Ibaraki, Japan. twada@md.tsukuba.ac.jp
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Wada
authors.forename: Isao
authors.initials: I
authors.lastname: Uemaetomari
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Murashita
authors.forename: Tadamichi
authors.initials: T
authors.lastname: Tobita
authors.forename: Shigeki
authors.initials: S
authors.lastname: Tsuji
authors.forename: Keiji
authors.initials: K
authors.lastname: Tabuchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Okubo
authors.forename: Akira
authors.initials: A
authors.lastname: Hara
mesh_terms: D000287:Administration, Topical; D001623:Betamethasone / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use*; D004802:Eosinophilia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010034:Otitis Media with Effusion / Q000150:complications / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D002227:Carbazoles; D005938:Glucocorticoids; D010975:Platelet Aggregation Inhibitors; D017482:Receptors, Thromboxane; D013449:Sulfonamides; D001623:Betamethasone; C063119:ramatroban